|Alina Puchnarewicz, Jolanta Tobolczyk, Marek Szczepański 2 , Danuta Rutkowska-Rogacz, Jerzy Hofman|
The aim of study was to evaluate the influence of inhaled budesonide on selected parameters of bone metabolism (carboxyterminal propeptid of type I procollagen (PICP), carboxyterminal piridinoline crosslinked telopeptide of type I collagen (ICTP), and osteocalcin. The study included 25 children with chronic mild bronchial asthma (aged 4-17 years, mean: 11,2 years). Children were treated with inhaled budesonide at the dose of 1200µg/day for 14 days, then 800µg/day for 10 weeks, thereafter 400 µg/day for 3 months. Serum levels of PICP, ICTP were determined with radioimmunoassay (RIA, Orion Diagnostica). Osteocalcin was measured using a commercial OSTK-PR radioimmunoassay (Cis, Gif sur Yvette. France). Blood samples were collected after 3 and 6 months of treatment.
Osteocalcin (136.7±61.4µg/L) and PICP (459.4±161.5µg/L) concentrations were significantly decreased after 3 months of treatment in comparison with control group (150.8±49.1 and 497.2±123.0µg/L, respectively). Osteocalcin concentration significantly (p<0.001) decreased after 6 months in comparison with 3 months of treatment. ICTP did not change significantly.
Decreased PICP and osteocalcin concentration suggests the decreased rate of bone formation and might be clinically useful as a marker of early adverse effects of glucocorticoids on bone tissue.
Alergia Astma Immunologia, 2001, 6(2), 95-99
keywords: astma, budezonid, metabolizm kostny, dzieci, asthma, budesonide, bone metabolism, children
pages: from 95 to 99
|estimated time of download (79 kB)|